JPRN-UMIN000023959已完成未知
Effect of canagliflozin on urinary albumin excretion in type 2 diabetic patients with microalbuminuria (pilot study) - Effect of canagliflozin on microalbuminuria in type 2 diabetic patients
akakinen clinic Medical Corporation Kensei-kai0 个研究点目标入组 20 人开始时间: 2016年9月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Type 1 diabetes 2. The following drugs are administered (the date of submission of informed consent)SGLT2 inhibitor Insulin GLP-1receptor agonist 3. History of hypersensitivity to canagliflozin 4. Has severe ketosis, diabetic coma or semi-coma 5. Has severe infection, trauma or perioperative 6. Possible or definitive pregnant women or nursing mother 7. Has malignant tumor or suspicious for 8. Has urinary tract infection 9. Has NYHA class IV heart failure 10. Has severe anemia 11. Considered not eligible for the study by principal or other investigators due to other reasons
研究者
相似试验
已完成
4 期
EUROBEAT StudyType 2 diabetes mellitusJPRN-jRCTs051200147Makino Hisashi80
招募中
4 期
Effect of Tofogliflozin on Urine Albumin-to-Creatinine Ratio Compared to Metformin Hydrochloride in Diabetic Kidney DiseaseJPRN-jRCTs031210339Kuwahara Koichiro120
已完成
不适用
The protective effect of canagliflozin on renal function in obese patients with T2DMObese T2DM with nephropathyJPRN-UMIN000018711Division of Nephrology, Nippon Medical School20
已完成
不适用
Effects of canagliflozin on the glycemic control and plasma GLP-1 levels.Type 2 diabetes mellitusJPRN-UMIN000018345akakinen clinic45
已完成
不适用
Effects of Canagliflozin on microbiota and glycometabolism, kidney function of patients with diabetic nephropathydiabetic nephropathyJPRN-UMIN000020710Keio University, School of Medicine33